The tweet was deleted by the author.
But we saved everything 🙂.
Tyra Biosciences has initiated the SURF302 study, focusing on an investigational oral therapeutic approach for patients with non-muscle invasive bladder cancer (NMIBC).
The company aims to reduce the treatment burden for these patients by rethinking the standard management of IR-NMIBC, potentially unlocking new possibilities in care. The SURF302 study will assess the efficacy and safety of this innovative oral therapy, offering hope for improved patient outcomes.
Tyra Biosciences has recently intensified its focus on novel therapies for urologic cancers, engaging clinical experts and patient advocates in research initiatives. The company’s efforts in this area were outlined in prior coverage of its strategy for urologic cancer treatment innovation. These moves form part of its broader pipeline targeting bladder and other urologic malignancies.